Echo Therapeutics Inc. will complete a clinical study of its Symphony non-invasive, wireless transdermal continuous glucose monitoring system by the fourth quarter, in what would be a major step forward for a company that has burned through more than $60 million trying to bring its products to market.
MicroCHIPS Inc. may have been the result of divine inspiration (as the story goes, MIT professor Robert Langer thought of the idea while watching PBS), but it took people like Maggie Pax to turn his vision into a suite of implantable devices that could one day revolutionize medicine.
Shawna Gvazdauskas has a knack for bringing medical devices to market. The 53-year-old is on the third start-up of her 30-year career. In March, she left insulin management maker Insulet, where she helped bring the company’s flagship Omnipod to market, for a new challenge at Isis Biopolymer Inc., which is developing a new generation of non-invasive drug delivery patches.
Taris Biomedical hit the ground running, raising $15 million from venture fund backers for its launch.
The Lexington-based drug-device developer, which is aiming to leverage lidocaine delivery technology developed at MIT to treat bladder conditions, said (PDF) Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners led the investment round.
MassDevice caught Rob Campbell, Insulet Corp.‘s vice president of clinical research, on his way to dinner in Paris after a day spent lining up a distribution deal for the company’s flagship OmniPod insulin management system.
European Union regulators gave the nod for the device to hit the market there, meaning the Bedford-based diabetes device maker is cleared to start selling the OmniPod in countries that recognize the EU’s CE Mark.
The Google-sponsored awards are given to products that “excel in marketplace, innovation, marketplace success, technological innovation, market structure, innovation, and societal impact.” Past winners include Apple Computer, Johnson & Johnson and Chrysler.